Nonmuscle invasive bladder cancer： a primer on immunotherapy

Intravesical Bacillus Calmette-Guerin （BCG） has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, mo...

Full description

Saved in:
Bibliographic Details
Published in:Cancer biology & medicine 2016-06, Vol.13 (2), p.194-205
Main Authors: Maruf, Mahir, Brancato, Sam J, Agarwal, Piyush K
Format: Article
Language:English
Subjects:
Bacillus Calmette-Gu&#233rin (BCG)
bladder cancer
immunotherapy
Review
Urothelial cell carcinoma
上皮细胞
免疫反应
免疫治疗剂
入门
单克隆抗体
浸润性
肌
膀胱癌
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Intravesical Bacillus Calmette-Guerin （BCG） has long been the gold standard treatment of nonmuscle invasive bladder cancer. Recently, there has been an emergence of novel immunotherapeutic agents, which have shown promise in the treatment of urothelial cell carcinoma. These agents aim to augment, modify, or enhance the immune response. Such strategies include recombinant BCG, monoclonal antibodies, vaccines, gene therapy, and adoptive T-cell therapy. Here, we review the emerging immunotherapeutics in the treatment of nonmuscle invasive bladder cancer.
ISSN:2095-3941
2095-3941
DOI:10.20892/j.issn.2095-3941.2016.0020